VIP receptor antagonists and chemotherapeutic drugs inhibit the growth of breast cancer cells

T. W. Moody, J. Leyton, D. Chan, D. C. Brenneman, M. Fridkin, E. Gelber, A. Levy, I. Gozes

Research output: Contribution to journalArticlepeer-review

Abstract

The effects of vasoactive intestinal peptide (VIP) antagonists on breast cancer cells were investigated. (N-stearyl, norleucine17)VIP hybrid ((SN)VIPhyb) inhibited specific 125I-VIP binding to MCF7, SKBR3, T47D ZR75-1 and MDA-MB231 cells with high affinity (IC50 values of 0.03-0.06 μM). (SN)VIPhyb,1 μM, inhibited the ability of 10 nM VIP to cause elevation of cAMP and to increase c-fos mRNA. Micromolar concentrations of (SN)VIPhyb inhibited the proliferation of MDA-MB231 or MCF7 cells using a MTT and clonogenic assay. Using a MTT assay, (SN)VIPhyb enhanced the ability of taxol and doxorubicin to inhibit breast cancer growth. Using nude mice bearing MDA-MB231 xenografts, VIPhyb potentiated the ability of taxol to inhibit proliferation. The results indicate that VIP receptor antagonists increase the ability of chemotherapeutic drugs to kill breast cancer cells.

Original languageEnglish
Pages (from-to)55-64
Number of pages10
JournalBreast Cancer Research and Treatment
Volume68
Issue number1
DOIs
StatePublished - 2001

Keywords

  • Antagonist
  • Breast cancer
  • Doxorubicin
  • Proliferation
  • Taxol
  • VIP

Fingerprint

Dive into the research topics of 'VIP receptor antagonists and chemotherapeutic drugs inhibit the growth of breast cancer cells'. Together they form a unique fingerprint.

Cite this